FULCRUM THERAPEUTICS INC

NASDAQ: FULC (Fulcrum Therapeutics, Inc.)

最近更新时间: 2天之前, 5:28PM

12.99

4.09 (45.96%)

前收盘价格 8.90
收盘价格 12.85
成交量 24,674,474
平均成交量 (3个月) 670,068
市值 702,998,528
价格/销量 (P/S) 2.66
股市价格/股市净资产 (P/B) 2.43
52周波幅
2.32 (-82%) — 15.74 (21%)
利润日期 29 Oct 2025
营业毛利率 -0.64%
营业利益率 (TTM) -13.00%
稀释每股收益 (EPS TTM) -0.010
季度收入增长率 (YOY) -100.00%
总债务/股东权益 (D/E MRQ) 3.55%
流动比率 (MRQ) 28.71
营业现金流 (OCF TTM) 7.81 M
杠杆自由现金流 (LFCF TTM) 4.40 M
资产报酬率 (ROA TTM) -2.74%
股东权益报酬率 (ROE TTM) -0.23%

市场趋势

短期 中期
行业 Biotechnology (US) 看涨 混合的
Biotechnology (全球的) 看涨 混合的
股票 Fulcrum Therapeutics, Inc. 看涨 看涨

AIStockmoo 评分

-0.8
分析师共识 1.5
内部交易活动 NA
价格波动 -5.0
技术平均移动指标 0.0
技术振荡指标 0.5
平均 -0.75

相关股票

股票 市值 DY P/E(TTM) P/B
FULC 703 M - - 2.43
IONS 13 B - - 21.49
RNA 11 B - - 5.70
ARWR 10 B - - 17.90
NUVL 8 B - - 9.65
CDTX 7 B - - 16.47

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 1.82%
机构持股比例 96.20%
52周波幅
2.32 (-82%) — 15.74 (21%)
目标价格波幅
7.00 (-46%) — 25.00 (92%)
25.00 (HC Wainwright & Co., 92.46%) 购买
18.50 (42.42%)
7.00 (B of A Securities, -46.11%) 卖出
平均值 17.17 (32.18%)
总计 4 购买, 1 保留, 1 卖出
平均价格@调整类型 12.78
公司 日期 目标价格 调整类型 价格@调整类型
B of A Securities 09 Dec 2025 7.00 (-46.11%) 卖出 12.99
Cantor Fitzgerald 08 Dec 2025 24.00 (84.76%) 购买 12.99
HC Wainwright & Co. 08 Dec 2025 25.00 (92.46%) 购买 12.99
24 Nov 2025 18.00 (38.57%) 购买 11.74
Piper Sandler 08 Dec 2025 23.00 (77.06%) 购买 12.99
30 Oct 2025 16.00 (23.17%) 购买 8.60
RBC Capital 08 Dec 2025 10.00 (-23.02%) 保留 12.99
30 Oct 2025 7.00 (-46.11%) 保留 8.60
Truist Securities 24 Nov 2025 14.00 (7.78%) 购买 11.74

该时间范围内无数据。

日期 类型 细节
08 Dec 2025 公告 Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
06 Dec 2025 公告 Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
05 Dec 2025 公告 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Dec 2025 公告 Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
07 Nov 2025 公告 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Nov 2025 公告 Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
29 Oct 2025 公告 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
22 Oct 2025 公告 Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
14 Oct 2025 公告 Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
10 Oct 2025 公告 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Sep 2025 公告 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票